Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Gross Profit
Apontis Pharma AG
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Gross Profit
€23.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Gross Profit
€26.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Merck KGaA
XETRA:MRK
|
Gross Profit
€12.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Gross Profit
€749.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Gross Profit
€91.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Gross Profit?
Gross Profit
23.2m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Gross Profit amounts to 23.2m EUR.
What is Apontis Pharma AG's Gross Profit growth rate?
Gross Profit CAGR 3Y
-3%
Over the last year, the Gross Profit growth was -34%. The average annual Gross Profit growth rates for Apontis Pharma AG have been -3% over the past three years .
You don't have any saved screeners yet